Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP)

Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP)

Sponsors

Lead Sponsor: Centre Hospitalier Universitaire Dijon

Source Centre Hospitalier Universitaire Dijon
Brief Summary

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a peripheral destruction of platelets responsible for bleedings.

Monocytes/macrophages play a double role by phagocyting platelets recognized by autoantibodies and by maintaining the autoimmune response via their antigen-presenting cell functions.

Fcgamma receptors (FcγR), that are represented by activating receptors (FcγRI, FcγRIIa, FcγRIII) and an inhibiting one (FcγRIIb), are involved in the regulation of macrophages and have been reported to be dysregulated in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematous.

The aim of this study is to compare the expression of FcγR in patients with ITP on circulating monocytes and on splenic macrophages.

Overall Status Recruiting
Start Date October 2, 2014
Completion Date October 2020
Primary Completion Date October 2018
Study Type Observational
Primary Outcome
Measure Time Frame
1. The expressions of the activating FcγRs and the inhibiting receptor (FcγRIIb) on monocytes will be compared between ITP patients at diagnosis and controls - physiological parameter through study completion, an average of 2 years
Secondary Outcome
Measure Time Frame
1. The expressions of the activating FcγRs and the inhibiting receptor (FcγRIIb) on splenic macrophages will be compared between ITP patients and controls. - physiological parameter through study completion, an average of 2 years
Enrollment 70
Condition
Intervention

Intervention Type: Biological

Intervention Name: blood sample

Intervention Type: Procedure

Intervention Name: spleen sample

Eligibility

Sampling Method: Probability Sample

Criteria:

Inclusion Criteria:

ITP group

- Patients who have provided written consent

- Patients over 18 years

- Patients with national health insurance

- Patients with ITP, defined as thrombocytopenia < 100 G/L, after exclusion of infection- or drug-related thrombocytopenia and malignant hemopathy.

Control Group

- Persons who have provided a written consent

- Persons over 18 years

- Persons with national health insurance

- Persons without autoimmune disease

Exclusion Criteria:

- Patients under guardianship

- Pregnancy

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: Accepts Healthy Volunteers

Overall Contact

Last Name: Bernard BONNOTTE

Phone: 3.80.29.34.32

Phone Ext.: 33

Email: [email protected]

Location
Facility: Status: Contact: CHU Dijon Bourgogne Bernard BONNOTTE 3.80.29.34.32 33 [email protected]
Location Countries

France

Verification Date

March 2018

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Arm Group

Label: patient

Label: control

Acronym PTI Fc
Study Design Info

Observational Model: Case-Control

Time Perspective: Prospective

Source: ClinicalTrials.gov